NCT00169455View on ClinicalTrials.gov

Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Rotavirus Gastroenteritis
Interventions
BIOLOGICAL

Live attenuated human rotavirus vaccine

Trial Locations (2)

10400

GSK Investigational Site, Bangkok

10700

GSK Investigational Site, Bangkok

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY